Literature DB >> 3245701

Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

C C Knapp1, J Sierra-Madero, J A Washington.   

Abstract

Cefpodoxime, cefixime, and ceftriaxone inhibited Branhamella catarrhalis at less than or equal to 1 microgram/ml, beta-hemolytic streptococci at less than or equal to 0.25 microgram/ml, Neisseria meningitidis at less than or equal to 0.06 microgram/ml, and Haemophilus influenzae (other than beta-lactamase-negative, ampicillin-resistant isolates) at less than or equal to 0.12 microgram/ml. The MICs for 50% of isolates of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae were less than or equal to 1 microgram/ml for all three cephalosporins. The MICs of each cephalosporin for 90% of staphylococci, enterococci, and Pseudomonas aeruginosa isolates were greater than 16 micrograms/ml. Inoculum effects were noted with cefpodoxime and cefixime with beta-lactamase-positive H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3245701      PMCID: PMC176041          DOI: 10.1128/AAC.32.12.1896

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  In vitro activity of U-76,252 (CS-807), a new oral cephalosporin.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.

Authors:  C J Shanholtzer; L R Peterson; M L Mohn; J A Moody; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Studies on orally active cephalosporin esters.

Authors:  K Fujimoto; S Ishihara; H Yanagisawa; J Ide; E Nakayama; H Nakao; S Sugawara; M Iwata
Journal:  J Antibiot (Tokyo)       Date:  1987-03       Impact factor: 2.649

  4 in total
  29 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.

Authors:  F Schumacher-Perdreau; B Jansen; G Peters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

3.  Microbiological evaluation of cefpodoxime proxetil.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Chitosan-based electrospun nanofibrous mats, hydrogels and cast films: novel anti-bacterial wound dressing matrices.

Authors:  Sohail Shahzad; Muhammad Yar; Saadat Anwar Siddiqi; Nasir Mahmood; Abdul Rauf; Zafar-ul-Ahsan Qureshi; Muhammad Sabieh Anwar; Shahida Afzaal
Journal:  J Mater Sci Mater Med       Date:  2015-02-26       Impact factor: 3.896

5.  Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy.

Authors:  C Martin; X Viviand; A Cottin; V Savelli; C Brousse; E Ragni; C Richaud; M N Mallet
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.

Authors:  P O'Neill; K Nye; G Douce; J Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.

Authors:  N Takasugi; N Tsunaga; N Sugino; F Numa; H Kato
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.

Authors:  D Höffler; P Koeppe; M Corcilius; A Przyklinik
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.

Authors:  C Martin; X Viviand; M Alaya; F Lokiec; K Ennabli; R Said; M Pecking
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.